Distinct Regulation of Intrinsic Apoptosis in Benign and Malignant Thyroid Tumours

Abstract

Aberrations in the control of apoptosis represent a central feature of thyroid carcinogenesis. However, little is known about the regulation of components of the intrinsic apoptosis pathway in the thyroid. Using a real-time PCR approach we investigated the mRNA expression levels of Caspase3, Caspase3 s, xIAP, Bad, and β-actin in a panel of 79 thyroid tumours. Additionally, we assessed the activation status of Caspase3 by immunohistochemistry. In the present study, we provide first evidence for a deregulation of the intrinsic apoptosis pathway on the transcriptional and post-transcriptional level. Thus, malignant thyroid tumours revealed a significant downregulation of the proapoptotic Bad. In contrast Caspase3 s, an alternative splice variant of Caspase3 with anti-apoptotic characteristics, was upregulated in follicular and anaplastic cancers. Moreover, papillary thyroid tumours revealed a significant upregulation of Caspase3 mRNA. On the post-translational level, thyroid malignancies featured an impairment in the activation of Caspase3, since activated Caspase3 accumulated exclusively in the cytoplasm of thyroid cancer cells, whereas follicular adenoma and normal thyroid tissues showed no cytoplasmatic but nuclear Caspase3 distribution. Further knowledge on apoptosis-deregulation during thyroid carcinogenesis might confer diagnostic and therapeutic benefits in the management of thyroid cancer.

Key words

apoptosis - thyroid cancer - Caspase3 - Caspase3s - Bad - xIAP

References

• 1 Tokunaga E, Oki E, Egashira A, Sadanaga N, Morita M, Kakeji Y, Maehara Y. Deregulation of the Akt pathway in human cancer.  Curr Cancer Drug Targets. 2008;  8 27-36
• 2 Vegran F, Boidot R, Oudin C, Riedinger JM, Bonnetain F, Lizard-Nacol S. Overexpression of caspase-3 s splice variant in locally advanced breast carcinoma is associated with poor response to neoadjuvant chemotherapy.  Clin Cancer Res. 2006;  12 5794-5800
• 3 Li J, Yuan J. Caspases in apoptosis and beyond.  Oncogene. 2008;  27 6194-6206
• 4 Kamada S, Kikkawa U, Tsujimoto Y, Hunter T. Nuclear translocation of caspase-3 is dependent on its proteolytic activation and recognition of a substrate-like protein(s).  J Biol Chem. 2005;  280 857-860
• 5 Huang Y, Shin NH, Sun Y, Wang KK. Molecular cloning and characterization of a novel caspase-3 variant that attenuates apoptosis induced by proteasome inhibition.  Biochem Biophys Res Commun. 2001;  283 762-769
• 6 Eckelman BP, Salvesen GS, Scott FL. Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family.  EMBO Rep. 2006;  7 988-994
• 7 Levine B, Sinha S, Kroemer G. Bcl-2 family members: dual regulators of apoptosis and autophagy.  Autophagy. 2008;  4 600-606
• 8 Karger S, Weidinger C, Krause K, Sheu SY, Aigner T, Gimm O, Schmid K, Dralle H, Fuhrer D. FOXO3a: a novel player in thyroid carcinogenesis?.  Endocr Relat Cancer. 2009;  16 189-199
• 9 Krause K, Eszlinger M, Gimm O, Karger S, Engelhardt C, Dralle H, Fuhrer D. TFF3-based candidate gene discrimination of benign and malignant thyroid tumors in a region with borderline iodine deficiency.  J Clin Endocrinol Metab. 2008;  93 1390-1393
• 10 Krause K, Karger S, Gimm O, Sheu SY, Dralle H, Tannapfel A, Schmid KW, Dupuy C, Fuhrer D. Characterisation of DEHAL1 expression in thyroid pathologies.  Eur J Endocrinol. 2007;  156 1-8
• 11 Fuhrer D, Eszlinger M, Karger S, Krause K, Engelhardt C, Hasenclever D, Dralle H, Paschke R. Evaluation of insulin-like growth factor II, cyclooxygenase-2, ets-1 and thyroid-specific thyroglobulin mRNA expression in benign and malignant thyroid tumours.  Eur J Endocrinol. 2005;  152 785-790
• 12 Sherman SI. Tyrosine kinase inhibitors and the thyroid.  Best Pract Res Clin Endocrinol Metab. 2009;  23 713-722

Correspondence